IVD & LDT For Autoimmune Diseases Market - Global Forecast 2026-2032

The autoimmune disease IVD & LDT market is experiencing swift transformation, with innovative diagnostic technologies and evolving clinical practices redefining procurement priorities for healthcare organizations. Senior decision-makers navigating this environment must anticipate regulatory shifts and adapt to technology standards to secure growth and differentiation.

Market Snapshot: IVD & LDT for Autoimmune Diseases Market

The IVD & LDT for Autoimmune Diseases market expanded from USD 19.26 billion in 2025 to USD 20.28 billion in 2026 and is expected to reach USD 27.56 billion by 2032, representing a CAGR of 5.25%. Growth continues to accelerate amid increasing clinical need for precise and rapid autoimmune diagnostics, supported by fresh innovation and regulatory focus. Strategic planning should factor in not only market momentum but also the changing nature of laboratory operations and payer expectations across diverse global regions.

Scope & Segmentation

Assay/Test Types: Anti-Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, Rheumatoid Factor. Each test segment fulfills specific clinical roles from disease confirmation to ongoing monitoring, responding to a broad set of autoimmune diagnostic requirements.
Technologies: Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, Multiplex Immunoassay. These technologies offer adaptability for laboratories prioritizing speed, throughput, and sensitivity in both routine and complex cases.
Product Classifications: In Vitro Diagnostic Devices, Lab Developed Tests. The product spectrum serves varied regulatory and operational contexts, meeting the demand for both standardized and customizable diagnostic approaches.
End Users: Academic and Research Institutes, Diagnostic Laboratories, Hospital Laboratories, Reference Laboratories. Each end user segment presents distinct requirements for workflow integration, procurement pathways, and evidence-generation capacity within the market.
Applications: Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes. These application areas illustrate the market’s clinical breadth and its relevance to multiple disciplines across the healthcare continuum.
Sample Modalities: Dried Blood Spot, Plasma, Serum, Whole Blood. Modular sampling options facilitate accessibility and flexibility for laboratories adapting to various infrastructure and patient care needs.
Regions: Americas, Europe, Middle East & Africa, Asia-Pacific. Diverse regional regulatory environments and purchasing priorities drive differentiated adoption patterns and highlight the necessity of targeted strategies in market expansion.

Key Takeaways for Senior Decision-Makers

Clinical laboratories are transitioning toward advanced algorithmic diagnostics enabled by access to novel serological markers and integrated digital platforms. This shift allows for greater diagnostic accuracy and streamlined decision-making.
Health systems and payers are emphasizing the clear demonstration of clinical utility and cost-effectiveness, elevating the importance of robust validation procedures and continuous outcome monitoring in procurement processes.
Adoption of high-throughput and multiplex diagnostic platforms is enhancing speed and enabling more nuanced disease classification, directly supporting improved workflow efficiencies in both central and reference lab settings.
Regional dynamics influence market engagement: North American markets prioritize evidence rich procurement and strong support infrastructure, while the Asia-Pacific region focuses on manufacturability and scalability to address rising autoimmune disease incidence.
Collaborative initiatives among manufacturers, laboratories, and research stakeholders are critical, as they accelerate clinical validation efforts and strengthen competitive positioning amid evolving regulations.

Tariff Impact on Supply Chain Resilience

Tariff changes and fluctuating trade policies continue to impact the sourcing costs for diagnostic reagents, consumables, and components. Manufacturers are responding by adjusting sourcing strategies, localizing production processes, and employing more adaptable distributor contracts. Laboratories improving their supplier evaluation systems and maintaining adaptable inventory levels are better positioned to manage cost fluctuations and operational continuity, despite episodic volatility in global supply chains.

Methodology & Data Sources

The market analysis employs a mixed-methods framework, integrating structured interviews with laboratory and clinical leaders, a thorough synthesis of existing literature, and systematic triangulation of quantitative and qualitative evidence. All findings undergo rigorous cross-verification against published technical and regulatory sources to ensure credibility and contextual accuracy for each regional market environment.

Why This Report Matters

Provides procurement, R&D, and leadership teams with the insights needed to align product roadmaps and investment strategies in step with clinical, technology, and reimbursement trends.
Offers actionable segmentation and geographic insights, empowering decision-makers to refine market entry, develop supply chain strategies, and evaluate partnership opportunities more effectively.
Facilitates improved dialogue with payers and procurement bodies, enhancing commercial planning and supply chain resilience while supporting growth in increasingly complex healthcare markets.

Conclusion

Technological innovation, rigorous clinical validation, and adaptable operations are fundamental in shaping the future of autoimmune disease diagnostics. Organizations focused on scalable and collaborative approaches are best positioned to navigate evolving industry demands and achieve long-term market impact.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

8.1. Anti Cyclic Citrullinated Peptide
8.2. Antinuclear Antibody
8.3. Celiac Disease
8.4. Rheumatoid Factor

9. IVD & LDT For Autoimmune Diseases Market, by Technology

9.1. Chemiluminescence Immunoassay
9.2. Enzyme Linked Immunosorbent Assay
9.3. Fluorescence Immunoassay
9.4. Multiplex Immunoassay

10. IVD & LDT For Autoimmune Diseases Market, by Product Type

10.1. In Vitro Diagnostic
10.2. Lab Developed Test

11. IVD & LDT For Autoimmune Diseases Market, by Sample Type

11.1. Dried Blood Spot
11.2. Plasma
11.3. Serum
11.4. Whole Blood

12. IVD & LDT For Autoimmune Diseases Market, by End User

12.1. Academic And Research Institutes
12.2. Diagnostic Laboratories
12.3. Hospital Laboratories
12.4. Reference Laboratories

13. IVD & LDT For Autoimmune Diseases Market, by Application

13.1. Celiac Disease
13.2. Multiple Sclerosis
13.3. Rheumatoid Arthritis
13.4. Systemic Lupus Erythematosus
13.5. Type 1 Diabetes

14. IVD & LDT For Autoimmune Diseases Market, by Region

14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific

15. IVD & LDT For Autoimmune Diseases Market, by Group

15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea

17. United States IVD & LDT For Autoimmune Diseases Market
18. China IVD & LDT For Autoimmune Diseases Market

19. Competitive Landscape

19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Abbott Laboratories
19.6. Adaptive Biotechnologies Corporation
19.7. Agilent Technologies Inc.
19.8. Atlas Link Technology Co., Ltd
19.9. Becton, Dickinson and Company
19.10. Bio-Rad Laboratories Inc.
19.11. bioMérieux SA
19.12. Corgenix, Inc.
19.13. Danaher Corporation
19.14. DiaSorin S.p.A.
19.15. EUROIMMUN AG
19.16. F. Hoffmann-La Roche Ltd.
19.17. Grifols, S.A.
19.18. Hologic Inc.
19.19. ImmunoScience India Pvt. Ltd.
19.20. Ortho Clinical Diagnostics, Inc.
19.21. PerkinElmer, Inc.
19.22. Quest Diagnostics, Inc.
19.23. Quidel Corporation
19.24. Siemens Healthineers AG
19.25. Sysmex Corporation
19.26. Thermo Fisher Scientific Inc.
19.27. Trinity Biotech plc

List of Figures

FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 109. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 111. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 120. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 122. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 125. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 138. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 142. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 144. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 145. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 146. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 147. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 156. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 158. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 159. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 161. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 165. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 166. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 167. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 168. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 170. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 172. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 173. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 174. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 175. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 185. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 186. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 187. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 188. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 189. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 190. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this IVD & LDT For Autoimmune Diseases market report include:

Abbott Laboratories
Adaptive Biotechnologies Corporation
Agilent Technologies Inc.
Atlas Link Technology Co., Ltd
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
bioMérieux SA
Corgenix, Inc.
Danaher Corporation
DiaSorin S.p.A.
EUROIMMUN AG
F. Hoffmann-La Roche Ltd.
Grifols, S.A.
Hologic Inc.
ImmunoScience India Pvt. Ltd.
Ortho Clinical Diagnostics, Inc.
PerkinElmer, Inc.
Quest Diagnostics, Inc.
Quidel Corporation
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific Inc.
Trinity Biotech plc

Table Information

Report Attribute	Details
No. of Pages	187
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 20.28 Billion
Forecasted Market Value ( USD ) by 2032	$ 27.56 Billion
Compound Annual Growth Rate	5.2%
Regions Covered	Global
No. of Companies Mentioned	24

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3423EUR$3,939USD£2,979GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3693EUR$4,249USD£3,214GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5005EUR$5,759USD£4,356GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6057EUR$6,969USD£5,271GBP

Market Snapshot: IVD & LDT for Autoimmune Diseases Market

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Tariff Impact on Supply Chain Resilience

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Autoimmune Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, and Region: (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa)

Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2025-2033

Autoimmune Disease Diagnosis Market Report 2025

Autoimmune Disease Diagnosis - Global Strategic Business Report

Autoimmune Disease Testing Market - Forecast from 2026 to 2031